The Global Breast Cancer Liquid Biopsy Market was valued at US$ 90,269.9 Thousands in 2019 and is expected to reach US$ 3,70,325.0 Thousands by 2027 growing at a Compounded Annual Growth Rate (CAGR) of 19.3% during the forecast period.
The Market is studied through the below listed segments. This segmentation has been built taking in account the material impact that each of these segments have on the overall ecosystem of the Breast Cancer Liquid Biopsy Market.
By Product & Service
The Reagent Kits sub-segment has the largest impact on the Breast Cancer Liquid Biopsy Market when segmented By Product & Service with a share of ~72%
By Circulating Biomarker
Circulating Tumor Cells
Circulating Tumor DNA
The Circulating Tumor Cells sub-segment has the largest share in the Breast Cancer Liquid Biopsy Market when segmented By Circulating Biomarker with a share of ~58%
The largest sub-segment within the Breast Cancer Liquid Biopsy Market, when segmented By Application, is Diagnostics with a share of ~55% Regional Analysis:
From a geographic segmentation perspective, the report focuses on the regions that have a material and significant effect on the market dynamics. The broad level coverage of the report includes the regions and key countries within the regions of Global, North America, Europe, APAC, MEA
The North America Region has the largest share in the Breast Cancer Liquid Biopsy Market from a Geographic Analysis point of view with a share of ~45%
The Breast Cancer Liquid Biopsy Market is fairly fragmented. While the key companies continue to drive innovation and, in most cases, adopt digital transformations, the overall competitive ecosystem is dominated by Market leaders as well as emerging players with niche offerings. This Breast Cancer Liquid Biopsy Market report profiles some of the key market players while reviewing significant market developments and strategies adopted by them. While looking at Organic and Inorganic strategies separately, the report studies not only outlook based (short-mid-long term), but also strategy based (strategic vs operational) market activity.
Key Companies profiled in this report include:
F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.)
Fluxion Biosciences, Inc.
Menarini Group (Menarini Silicon Biosystems, Inc.)
Myriad Genetics, Inc.
NeoGenomics Laboratories, Inc.
Thermo Fisher Scientific Inc.
Guardant Health, Inc.
While most of the Key Profiles are of Market Leaders, the profiling involves coverage of the market ecosystem. Based on the Market Strategy that a client is exploring, the Competitive Landscape is customized to make the CI data more actionable and relevant for the strategy execution.
Company profiles usually include:
Products / Services Overview
The Covid19 pandemic has transformed the market landscape. The second-wave in 2021 has highlighted the importance of Business Resilience and is putting lot of impetus on the business strategies involving bottom-line management like vendor-management, cost-optimization, etc., This report covers the aftermath of the Covid19 catastrophe and the key trends that need to be incorporate in Business plans. Report Customization: Our dynamic and proprietary data-mining technology has given us the flexibility to maintain both precision and speed while delivering exclusive and custom insights to our clients. We conduct customization of the Research data on all key fronts
Regional, Segment, Competitive landscape level. For every report-purchase, we offer 25 free analyst-hours to address critical factor sought in the Research activity Report Scope:
From a business-objective perspective, the Report details out the key take-aways necessary to formulate business strategies like:
New product launch
New client acquisition
New opportunity mapping (market level and geography level)
Cost optimization strategies
Inorganic expansion plans ......and more.
Ask for free product review call with the author
Share your specific research requirements for a customized report
Request for due diligence and consumer centric studies
Request for study updates, segment specific and country level reports
Chapter 1. Research Objective 1.1 Objective, Definition & Scope 1.2 Methodology 1.2.1 Primary Research 1.2.2 Secondary Research 1.2.3 Market Forecast - Estimation & Approach 1.2.4 Assumptions & Assessments 1.3 Insights and Growth - Relevancy Mapping 1.3.1 FABRIC Platform 1.4 Data mining & efficiency Chapter 2. Executive Summary 2.1 Breast Cancer Liquid Biopsy Market Overview 2.2 Interconnectivity & Related markets 2.3 Ecosystem Map 2.4 Breast Cancer Liquid Biopsy Market Business Segmentation 2.5 Breast Cancer Liquid Biopsy Market Geographic Segmentation 2.6 Competition Outlook 2.7 Key Statistics Chapter 3. Strategic Analysis 3.1 Breast Cancer Liquid Biopsy Market Revenue Opportunities 3.2 Cost Optimization 3.3 Covid19 aftermath - Analyst view 3.4 Breast Cancer Liquid Biopsy Market Digital Transformation Chapter 4. Market Dynamics 4.1 DROC 4.1.1 Drivers 4.1.2 Restraints 4.1.3 Opportunities 4.1.4 Challenges 4.2 PEST Analysis 4.2.1 Political 4.2.2 Economic 4.2.3 Social 4.2.4 Technological 4.3 Market Impacting Trends 4.3.1 Positive Impact Trends 4.3.2 Adverse Impact Trends 4.4 Porter's 5-force Analysis 4.5 Market News - By Segments 4.5.1 Organic News 4.5.2 Inorganic News Chapter 5. Market Segmentation The Breast Cancer Liquid Biopsy Market has been analysed to include the below segmentation: By Product & Service ? Reagent Kits ? Instruments ? Services By Circulating Biomarker ? Circulating Tumor Cells ? Extracellular Vesicles ? Circulating Tumor DNA By Application ? Diagnostics ? Prognostics ? Risk assessment Chapter 5A. Regional Segmentation The Breast Cancer Liquid Biopsy Market has been analysed by studying the following regions: North America ? By Product & Service ? By Circulating Biomarker ? By Application Europe ? By Product & Service ? By Circulating Biomarker ? By Application APAC ? By Product & Service ? By Circulating Biomarker ? By Application LatAm ? By Product & Service ? By Circulating Biomarker ? By Application MEA ? By Product & Service ? By Circulating Biomarker ? By Application **The Regions are further studied to analyse the major countries within the respective regions. The coverage of the country level data is dynamic and is updated regularly based on the market movements. Normally, the countries covered in the report include: ? North America - United States, Canada, Mexico; ? Europe - United Kingdom, France, Italy, Germany, Spain, Rest of Europe; ? Asia Pacific - China, India, Japan, South Korea, Rest of APAC; ? Middle East & Africa - South Africa, GCC Countries, Rest of MEA; ? Latin America - Brazil, Argentina, Rest of LatAm; Chapter 6. Market Use case studies Chapter 7. KOL Recommendations Chapter 8. Investment Landscape 8.1 Breast Cancer Liquid Biopsy Market Investment Analysis 8.2 Market M&A 8.3 Market Fund Raise & Other activity Chapter 9. Breast Cancer Liquid Biopsy Market - Competitive Intelligence 9.1 Company Positioning Analysis 9.1.1 Positioning - By Revenue 9.1.2 Positioning - By Business Score 9.1.3 Legacy Positioning 9.2 Competitive Strategy Analysis 9.2.1 Organic Strategies 9.2.2 Inorganic Strategies Chapter 10. Key Company Profiles *The Breast Cancer Liquid Biopsy Market Report profiles companies based on the material impact they have on the market ecosystem. These are hence, to be read as 'Key Players' and not necessarily 'Market Leaders'. Companies are typically profiled to include: 10.x.1 Company Fundamentals 10.x.2 Performance Overview 10.x.3 Product Overview 10.x.4 Recent Developments Key Companies profiled in this report include: ? Biocept Inc. ? F. Hoffmann-La Roche Ltd. (Foundation Medicine, Inc.) ? Fluxion Biosciences, Inc. ? Menarini Group (Menarini Silicon Biosystems, Inc.) ? Myriad Genetics, Inc. ? NeoGenomics Laboratories, Inc. ? Qiagen N.V. ? Sysmex Corporation ? Thermo Fisher Scientific Inc. ? Guardant Health, Inc. Chapter 11. Appendix 11.1 About AllTheResearch (ATR) 11.2 ATR Services 11.3 Author details 11.4 Terms & Conditions 11.5 Contact us